The majority of the patients received single-anti-PD-(L)1 therapy (n = 114, 90.5%) whereas the rest were treated with combination therapy mostly with histology matched chemotherapy for NSCLC (Keynote 189, Keynote 407). Here, CD274 is linked to non-small cell lung carcinoma.